J-L. van Laethem

650 total citations
14 papers, 520 citations indexed

About

J-L. van Laethem is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J-L. van Laethem has authored 14 papers receiving a total of 520 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Surgery and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J-L. van Laethem's work include Colorectal Cancer Treatments and Studies (5 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Colorectal and Anal Carcinomas (3 papers). J-L. van Laethem is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Colorectal and Anal Carcinomas (3 papers). J-L. van Laethem collaborates with scholars based in Belgium, Taiwan and Romania. J-L. van Laethem's co-authors include Jacques Devière, Michel Cremer, M O Peny, M Delhaye, Christine Decaestecker, Raphaël Maréchal, Marc Polus, Jean Closset, Isabelle Salmon and Nikoletta Nagy and has published in prestigious journals such as Gut, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J-L. van Laethem

12 papers receiving 507 citations

Peers

Countries citing papers authored by J-L. van Laethem

Since Specialization

Citations

This map shows the geographic impact of J-L. van Laethem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J-L. van Laethem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J-L. van Laethem more than expected).

Fields of papers citing papers by J-L. van Laethem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J-L. van Laethem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J-L. van Laethem. The network helps show where J-L. van Laethem may publish in the future.

Co-authorship network of co-authors of J-L. van Laethem

This figure shows the co-authorship network connecting the top 25 collaborators of J-L. van Laethem. A scholar is included among the top collaborators of J-L. van Laethem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J-L. van Laethem. J-L. van Laethem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	505P State of the art of gastrointestinal (GI) cancer trials for older patients (pts): A systematic review (SR) 2024 ·Annals of Oncology ·(unknown), (unknown), Everardo D. Saad, Giacomo Bregni, (unknown), Valentina Daprà, Chiara Conti, (unknown), (unknown), (unknown), (unknown), J-L. van Laethem, Francesco Sclafani	1
2	1519P Real-world evidence on long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan: NALLONG study 2024 ·Annals of Oncology ·(unknown), (unknown), T. Macarulla Mercadé, C. Benedikt Westphalen, (unknown), Hiroki Imaoka, (unknown), Chris Verslype, Takuji Okusaka, B-Y. Ryoo, (unknown), (unknown), J-L. van Laethem	0
3	LBA2 Interim efficacy analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC) 2024 ·Annals of Oncology ·Francesco Sclafani, Giacomo Bregni, (unknown), Francesco Puleo, Philippe Vergauwe, Hans Prenen, (unknown), (unknown), (unknown), G. Anthoine, L. Moretti, María Gómez Galdón, Gabriel Liberale, (unknown), Karen Geboes, Javier Carrasco, Marc Van den Eynde, J-L. van Laethem, Marc Buyse, Alain Hendlisz	0
4	599P R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC) 2023 ·Annals of Oncology ·Javier Carrasco, (unknown), Anne Jouret‐Mourin, Paméla Baldin, Isabelle Sinapi, Darrell R. Schroeder, (unknown), Francesco Sclafani, Alain Hendlisz, J-L. van Laethem, (unknown), (unknown), (unknown), (unknown), Nicolas D. Huyghe, Isabelle Bar, Marc Van den Eynde	5
5	397P R-IMMUNE interim analysis: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with localized rectal cancer 2021 ·Annals of Oncology ·Javier Carrasco, (unknown), Isabelle Sinapi, (unknown), (unknown), (unknown), J-L. van Laethem, Nicolas D. Huyghe, Isabelle Bar, Alain Hendlisz, Karin Haustermans, Thierry Delaunoit, J.-C. Coche, (unknown), (unknown), Paméla Baldin, Marc Van den Eynde	13
6	933P Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study 2021 ·Annals of Oncology ·J-L. van Laethem, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stål, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, S. Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, (unknown), Michael Chisamore, A. Wang, Andrew X. Zhu	1
7	505TiP REGINA: A phase II trial of neoadjuvant regorafenib (rego) in combination with nivolumab (nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC) 2021 ·Annals of Oncology ·Giacomo Bregni, (unknown), (unknown), Paraskevas Gkolfakis, L. Moretti, (unknown), Pieter Demetter, Gabriel Liberale, Javier Carrasco, Karen Geboes, (unknown), Marc Peeters, Marc Van den Eynde, J-L. van Laethem, Philippe Vergauwe, Marc Buyse, Amélie Deleporte, Alain Hendlisz, Francesco Sclafani	2
8	Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study 2014 ·British Journal of Cancer ·Eric Van Cutsem, Li Cp, Elżbieta Nowara, Giuseppe Aprile, Malcolm J. Moore, (unknown), J-L. van Laethem, Chiun Hsu, Chee Kian Tham, Salomon M. Stemmer, Rainer W. Lipp, Ali Zeaiter, A. Fittipaldo, (unknown), Barbara Klughammer, Xue Meng, Tudor–Eliade Ciuleanu	35
9	How to identify older patients with cancer who should benefit from comprehensive geriatric assessment? 2012 ·Journal of Geriatric Oncology ·(unknown), Sandra De Breucker, (unknown), Anne Demols, (unknown), (unknown), Alain Kentos, Thierry Roumeguère, (unknown), Claire Nouwynck, J-L. van Laethem, Youri Sokolow, P Simon, Benjamin Bailly, (unknown), M. Marchand, Thierry Pepersack	15
10	High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma 2009 ·British Journal of Cancer ·Raphaël Maréchal, Pieter Demetter, Nikoletta Nagy, (unknown), Christine Decaestecker, Marc Polus, Jean Closset, Jacques Devière, Isabelle Salmon, J-L. van Laethem	148
11	Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study 2007 ·British Journal of Cancer ·Gontran Verset, Chris Verslype, Hendrik Reynaert, Ivan Borbath, (unknown), A. Vandebroek, Marc Peeters, (unknown), Sven Francque, Marianna Arvanitakis, J-L. van Laethem	32
12	Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study 2005 ·British Journal of Cancer ·Eric Van Cutsem, Luc Dirix, J-L. van Laethem, Simon Van Belle, Markus Borner, Manuel González Barón, A. Roth, R. Morant, E. Joosens, G. Gruia, (unknown), Harry Bleiberg	35
13	Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice 1998 ·Gut ·J-L. van Laethem, (unknown), H Louis, Fabienne Rickaert, Patrick Robberecht, Jacques Devière	81
14	Eradication of Barrett’s mucosa with argon plasma coagulation and acid suppression: immediate and mid term results 1998 ·Gut ·J-L. van Laethem, Michel Cremer, M O Peny, M Delhaye, Jacques Devière	152

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takanobu Tabuchi Breakdown of academic impact, for papers by Eiji Noda Breakdown of academic impact, for papers by Hong Jo Choi Breakdown of academic impact, for papers by Heiko Aselmann Breakdown of academic impact, for papers by Eugene A. Choi Breakdown of academic impact, for papers by Seong Woo Hong Breakdown of academic impact, for papers by Yuta Kasagi Breakdown of academic impact, for papers by Č Neoral